Evotec SE: Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
European life science company Evotec SE (NASDAQ:EVO) announced a priority reset to optimize its business to meet evolving market demand and focus on profitable growth in 2024 and beyond. The company is focusing on and rightsizing organizations to overcome the challenging market environment and return to sustainable and profitable growth. Shared R&D and Just–Evotec Biologics will replace EVT Execute & EVT Innovate segments in a streamlined reporting structure as of Q1 2024. The priority reset is
EQSAdhoc Evotec SE Key word Personnel Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer 23Apr2024 2038 CETCEST Disclosure of an inside information acc to Article 17 MAR of the Reg
Following the surprising departure of Evotec s CEO Werner Lanthaler, the company has found a permanent solution for its top management. Christian Wojczewski will take over the position of CEO from.